After a year of turmoil, cancer researchers see promising signs for mRNA vaccines

Key Points:

• Vita Sara Blechner was diagnosed with pancreatic cancer in March 2020, a disease with a very low survival rate, and opted to participate in an experimental mRNA-based vaccine trial at Memorial Sloan Kettering Cancer Center (MSK).
• The personalized mRNA vaccine, developed in collaboration with BioNTech, targets individual cancer mutations and showed promising results, with half of the 16 trial participants exhibiting strong immune responses and prolonged survival.
• Despite political and funding challenges to mRNA research following the Covid-19 pandemic, cancer researchers report ongoing support from the National Cancer Institute and pharmaceutical companies, with multiple mRNA vaccine trials underway for various cancers.
• mRNA cancer vaccines differ from traditional vaccines by teaching the immune system to recognize a patient’s unique tumor mutations, and researchers are also exploring generalized “off-the-shelf” mRNA vaccines to boost immune responses more rapidly.
• Blechner’s case exemplifies the potential of mRNA cancer vaccines, as she remains cancer-free six years after treatment, highlighting hope for new immunotherapy approaches against traditionally difficult cancers like pancreatic cancer.